Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme

被引：0
|
作者：
Gridelli, C [1 ]
Rossi, A [1 ]
Maione, P [1 ]
Musto, L [1 ]
Del Gaizo, F [1 ]
Airoma, G [1 ]
机构：
[1] SG Moscati Hosp, Avellino, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Gefitinib ('Iressa', ZD1839) given in the 'Iressa' Expanded Access Programme in patients with non-small-cell lung cancer
    Chioni, A
    Barbieri, F
    Baldini, E
    Orlandini, C
    Ricci, S
    Conte, PF
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S27
  • [2] Gefitinib ('Iressa', ZD1839) in heavily pretreated patients with metastatic non-small-cell lung cancer
    Martín-Algarra, S
    Gurpide, A
    Lopez-Picazo, JM
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S30 - S30
  • [3] Gefitinib ('Iressa', ZD1839) for patients with advanced non-small-cell lung cancer treated in the 'Iressa' Expanded Access Programme at a single institution in Brazil
    Katz, A
    Smaletz, O
    Simon, SD
    Rene, GC
    Hoff, PM
    Tabacof, J
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [4] Analysis of the efficacy and tolerability of gefitinib ('Iressa', ZD1839) in previously treated patients with non-small-cell lung cancer enrolled in the 'Iressa' Expanded Access Programme
    de Leeuw, K
    Schallier, D
    Sermijn, E
    Fontaine, C
    Neyns, B
    Samijn, I
    de Grève, J
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [5] Gefitinib ('Iressa', ZD1839) in relapsed non-small-cell lung cancer
    Reck, M
    Gatzemeier, U
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S33
  • [6] Gefitinib ('Iressa', ZD1839) as treatment for non-small-cell lung cancer
    Razis, E
    Papadopoulos, S
    Skarlos, D
    Exarchakos, M
    Christodoulou, C
    Karina, M
    Xylouri, M
    Labropoulos, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S32
  • [7] Gefitinib ('Iressa', ZD1839) in patients with pretreated stage IIIb-IV non-small-cell lung cancer entering the 'Iressa' Expanded Access Programme at the University Federico II, Naples
    Bianco, AR
    Damianov, V
    Matano, E
    Bianco, R
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [8] Refractory non-small-cell lung cancer: clinical experience with gefitinib ('Iressa', ZD1839) in 28 patients who entered the 'Iressa' Expanded Access Programme at the Sydney Cancer Centre
    Boyer, M
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [9] Gefitinib ('Iressa', ZD1839) in special patient populations (elderly ≥70 years or performance status ≥2) with advanced non-small-cell lung cancer:: a case series report from the 'Iressa' Expanded Access Programme
    Gridelli, C
    Maione, P
    Rossi, A
    Guerriero, C
    Barzelloni, ML
    Ferrara, C
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [10] Gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer patients progressed to chemotherapy
    Cortes-Funes, H
    Figueiras, MC
    Martín-Algarra, S
    Salinas, P
    Massutí, B
    Gascón, P
    Rosell, R
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S27
12345